RecruitingNot Applicable

Skeletal Muscle Function in Interstitial Lung Disease

Canada40 participantsStarted 2024-08-07

Plain-language summary

Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.

Who can participate

Age range40 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria for ILD Patients: * Age 40-80 years (inclusive) * A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses * Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis * Appropriate candidate for pulmonary rehabilitation * 6 minute walk distance 50m or more * Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air * Clinically stable for the preceding 6 weeks * Can fluently read and write in English Inclusion Criteria for Healthy Controls: * Age 40-80 (inclusive) * Normal pulmonary function (80-120% predicted) * No lung or cardiovascular disease * Can fluently read and write in English Exclusion Criteria for the ILD patients: * Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) * Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation * Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25% * Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program * Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit * Significan…

What they're measuring

Change in standardized dyspnea score during the constant load exercise test (visit 3)

Timeframe: Dyspnea will be measured once every minute during exercise on visit 3 (up to 7 weeks after baseline) until participants reach volitional exhaustion (assessed for up to 30 minutes)

Change in standardized dyspnea score during the constant load exercise test (visit 4)

Timeframe: Dyspnea will be measured once every minute during exercise on visit 4 (up to 8 weeks after baseline) until participants reach volitional exhaustion (assessed for up to 30 minutes)

Change in leg muscle strength measured following the constant load exercise test (visit 3)

Timeframe: Leg muscle strength will be measured before and after exercise (assessed for up to 40 minutes) on visit 3 (up to 8 weeks after baseline)

Change in leg muscle strength measured following the constant load exercise test (visit 4)

Timeframe: Leg muscle strength will be measured before and after exercise (assessed for up to 40 minutes) on visit 4 (up to 8 weeks after baseline)

Trial details

NCT IDNCT03800017

SponsorUniversity of British Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Olivia Ferguson, MSc

1-604-806-8835 Olivia.Ferguson@hli.ubc.ca

View on ClinicalTrials.gov More Interstitial Lung Disease trials